← back to search

Lewis L. Lanier

Universidad Católica de Santa Fe · AR
Area of research
Immunology · Radiology, Nuclear Medicine and Imaging
Research interest
Natural killer (NK) cells are a type of white blood cell that provides protection against microbial pathogens and tumors. Since the early 1980’s, our lab has investigated how NK cells distinguish between normal healthy cells and cells that are transformed or infected with viruses. NK cells express a diverse array of inhibitory and activating receptors on their cells surface that bind to ligands expressed on the cell surface of potential target cells.
h-index
165
citations
99,104
works
707
NIH funding
primary concept
Biology
email

Recent publications

Author Reply to Peer Reviews of Natural Killer Cell Receptor Signaling and Activation Depend on Cell Cycle Stages
2026cited by 0position: contributordoi
SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy
The Journal of Immunology 2025cited by 7position: lastdoi
SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy.
2025cited by 5position: contributordoi
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19
JCI Insight 2025cited by 2position: contributordoi
CITE-Seq Analysis Reveals a Differential Natural Killer Cell <i>SPON2</i> Expression in Cardiovascular Disease Patients Impacted by Human-Cytomegalovirus Serostatus and Diabetes.
2025cited by 1position: contributordoi
FcɛR1γ-based activating chimeric antigen receptor enhanced natural killer cell function against HLA-E+ cells
The Journal of Immunology 2025cited by 1position: firstdoi
FcɛR1γ-based Activating Chimeric Antigen Receptors enhanced Natural Killer cell function against HLA-E <sup>+</sup> cells
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 1position: firstdoi
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19
JCI Insight 2025cited by 1position: middledoi
Natural Killer Cell Receptor Signaling and Activation Depend on Cell Cycle Stages
2025cited by 0position: contributordoi
Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function
2025cited by 0position: contributordoi
CITE-Seq Analysis Reveals a Differential Natural Killer Cell SPON2 Expression in Cardiovascular Disease Patients Impacted by Human-Cytomegalovirus Serostatus and Diabetes. Int J Mol Sci. 2025 Feb 06; 26(3).
2025cited by 0position: selected
High-dimensional single-cell analysis of human natural killer cell heterogeneity
Nature Immunology 2024cited by 213position: middledoi
High-dimensional single-cell analysis of human natural killer cell heterogeneity.
2024cited by 171position: contributordoi
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.
2024cited by 110position: contributordoi
Five decades of natural killer cell discovery
The Journal of Experimental Medicine 2024cited by 51position: firstdoi
Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation
Nature Communications 2024cited by 37position: contributordoi
Five decades of natural killer cell discovery.
2024cited by 32position: contributordoi
<scp>ITAM</scp>‐based receptors in natural killer cells
Immunological Reviews 2024cited by 20position: lastdoi
ITAM-based receptors in natural killer cells.
2024cited by 16position: contributordoi
PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.
2024cited by 11position: contributordoi
Spleen Tyrosine Kinase (SYK) negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy
2024cited by 2position: contributordoi
Table S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi
Figure S3 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi
Data from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi
Figure S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi
Figure S3 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi
Data from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi
High-Dimensional Single-Cell Analysis of Natural Killer Cell Heterogeneity in Human Blood
2024cited by 0position: contributordoi
Figure S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi
Figure S2 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 53 papers (2019–2026)Oscar A. Aguilar · University of California San Francisco Medical Center22 papers (2020–2025)James A. Wells · AI Biosciences (United States)16 papers (2021–2024)Lawrence Fong · Royal North Shore Hospital16 papers (2023–2024)Hannah Driks · University of San Francisco15 papers (2024–2024)Robert Blelloch · The University of Sydney15 papers (2024–2024)Jiuling Yang · University of San Francisco15 papers (2024–2024)Li Wang · University of San Francisco15 papers (2024–2024)Cassandra D. Belair · University of San Francisco15 papers (2024–2024)James R. Byrnes · University of San Francisco15 papers (2024–2024)Lisa L. Kirkemo · University of San Francisco15 papers (2024–2024)Joseph C. Sun · National Heart Lung and Blood Institute8 papers (2012–2020)Avishai Shemesh · Harvard University7 papers (2021–2025)Gundula Min‐Oo · Gilead Sciences (United States)6 papers (2012–2014)Daniel R. Calabrese · Pulmonary Associates6 papers (2021–2025)John R. Greenland · University of California San Francisco Medical Center6 papers (2021–2025)Tsukasa Nabekura · Aichi Cancer Center5 papers (2013–2016)Avishai Shemesh · University of California, San Francisco5 papers (2022–2025)Natalie Bezman · Pfizer (United States)5 papers (2012–2014)Sonja Schrepfer · German Centre for Cardiovascular Research5 papers (2019–2024)